1. Scrip
  2. >>Business

Acquired Stada To Act As 'Core' For Future Bain and Cinven Bolt-Ons

 
• By Sten Stovall

Cinven and Bain seem likely to use German generics maker Stada as a nucleus around which to add smaller acquisitions, mostly in Europe, for an eventual exit by the private equity firms.

3D Core

Private equity firms Bain Capital and Cinven Partners LLP are buying German generics maker Stada Arzneimittel AG at an eye-watering takeover price to use its products and infrastructure as a core business around which smaller bolt-on deals can coalesce into a sizeable entity for an eventual sale, analysts say.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business

AstraZeneca COPD Drug Breztri Breezes Through Asthma Trials

 
• By Kevin Grogan

The triple therapy improves lung function in the Phase III KALOS and LOGOS studies

Transient FY26 For Syngene But Momentum In China +1 Projects

 
• By Anju Ghangurde

As biopharma derisks its business with China ‘rebalancing’ strategies, Syngene could convert majority of such pilots into full program contracts amid a challenging FY2025. The CRDMO also expects business discussions pertaining to a newly acquired US biologics site to mature into commercial opportunities.

Biogen’s Manufacturing Sites, Revenue Sources Protect It From Big Tariff Impact

 
• By Mandy Jackson

Biogen expects little impact from existing tariffs and any that may apply if the US exemption of pharma products is lifted, since 75% of its manufacturing is in the US and 55% of sales are ex-US.